# US 2002/0001614 A1 · Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0001614 A1
- Document ID: US20020001614A1
- Status: Published application
- Kind: A1
- Application number: 09/781,893
- Filed: 2001-02-09
- Published: 2002-01-03
- Earliest claimed: 2000-02-10
- Inventors: Kent Jorgensen; Jesper Davidsen; Charlotte Vermehren; Sven Frokjaer; Ole G. Mouritsen
- Web page: https://patentgrep.com/patent/US20020001614A1

## CPC

- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a lipid-based drug delivery system for administration of a lysolipid derivative present in prodrug from, said prodrug furthermore being a substrate for extracellular phospholipase A2 to the extent that an organic radical can be hydrolytically cleaved off, whereas the aliphatic group of the lysolipid derivative remains substantially unaffected, said system having included therein lipopolymers or glycolipids so as to present hydrophilic chains on the surface of the system. Particularly interesting lipid derivatives are ether lipids and ether lipids in which drug substance is covalently attached in the sn-2-position. Pharmaceutical compositions comprising the drug delivery system can be used in the targeted treatment of various disorders, e.g. cancer, infectious, and inflammatory conditions, etc., i.e. disorders and diseases associated with or resulting from increased levels of extracellular PLA2 activity in the diseased tissue.

## Claims

### Claim 1

A lipid-based drug delivery system for administration of an active drug substance selected from lysolipid derivatives, wherein the active drug substance is present in the lipid-based system in the form of a prodrug, said prodrug being a lipid derivative having (a) an aliphatic group of a length of at least 7 carbon atoms and an organic radical having at least 7 carbon atoms, and (b) a hydrophilic moiety, said prodrug furthermore being a substrate for extracellular phospholipase A2 to the extent that the organic radical can be hydrolytically cleaved off, whereas the aliphatic group remains substantially unaffected, whereby the active drug substance is liberated in the form of a lysolipid derivative which is not a substrate for lysophospholipase, said system having included therein lipopolymers or glycolipids so as to present hydrophilic chains on the surface of the system.

### Claim 2 (depends on 1)

A drug delivery system according to claim 1, wherein the lipopolymers or glycolipids are represented by at least a fraction of the prodrug.

### Claim 3 (depends on 1)

A drug delivery system according to claim 1, wherein the polymer of the lipopolymer is selected from polyethylene glycol, poly(lactic acid), poly(glycolic acid), poly(lactic acid)-poly(glycolic acid) copolymers, polyvinyl alcohol, polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatised celluloses.

### Claim 4 (depends on 1)

A drug delivery system according to claim 1, wherein the organic radical which can be hydrolytically cleaved off, is an auxiliary drug substance or an efficiency modifier for the active drug substance.

### Claim 5 (depends on 1)

A drug delivery system according to claim 1, wherein the prodrug is a lipid derivative of the following formula:
6
wherein
X and Z independently are selected from 0, CH2, NH, NMe, S, S(O), and S(O)2;
Y is —OC(O)—, Y then being connected to R2 via either the oxygen or carbonyl carbon atom;
R1 is an aliphatic group of the formula Y1Y2;
R2 is an organic radical having at least 7 carbon atoms;
where Y1 is —(CH2)n1—(CH═CH)n2—(CH2)n3—(CH═CH)n4—(CH2)n5—(CH═CH)n6—(CH2)n7—(CH═CH)n8r—(CH2)n9, and the sum of n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 9 to 29; n1 is zero or an integer of from 1 to 29, n3 is zero or an integer of from 1 to 20, n5 is zero or an integer of from 1 to 17, n7 is zero or an integer of from 1 to 14, and n9 is zero or an integer of from 1 to 11; and each of n2, n4, n6 and n8 is independently zero or 1; and Y2 is CH3 or CO2H; where each Y1—Y2 independently may be substituted with halogen or C1-4-alkyl,
R3 is selected from phosphatidic acid (PO2—OH), derivatives of phosphatidic acid and bioisosters to phosphatic acid and derivatives thereof.

### Claim 6 (depends on 5)

A drug delivery system according to claim 5, wherein R2 is an aliphatic group of a length of at least 7 carbon atoms.

### Claim 7 (depends on 6)

A drug delivery system according to claim 6, wherein R2 is a group of the formula Y1Y2.

### Claim 8 (depends on 1, 5)

A drug delivery system according to claim 1, wherein at least a fraction of the prodrug is of the formula defined in claim 5, wherein R3 is a derivative of phosphatidic acid to which a polymer selected from polyethylene glycol, poly(lactic acid), poly(glycolic acid), poly(lactic acid)-poly(glycolic acid) copolymers, polyvinyl alcohol, polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatised celluloses, is covalently attached.

### Claim 9 (depends on 1)

A drug delivery system according to claim 1, wherein the prodrug constitutes 15-100 mol % of the total dehydrated lipid-based system.

### Claim 10 (depends on 1)

A drug delivery system according to claim 1, wherein the lipopolymer constitutes 1-50 mol % of the total dehydrated system.

### Claim 11 (depends on 1)

A drug delivery system according to claim 1, wherein the lipid-based system is in the form of liposomes.

### Claim 12 (depends on 1)

A drug delivery system according to claim 1, which is in the form of liposomes wherein a second drug substance is incorporated.

### Claim 13 (depends on 12)

A drug delivery system according to claim 12, wherein the second drug substance is a therapeutically and/or prophylactically active substanceselected from (i) antitumor agents, (ii) antibiotics and antifungals, and (iii) antiinflammatory agents.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the lipid-based drug delivery system according to claim 1 and optionally a pharmaceutically acceptable carrier.

### Claim 15 (depends on 1)

A method for selectively drug targeting to neoplastic cells, e.g., to areas within the mammalian body, preferably a human, having a extracellular phospholipase A2 activity which is at least 25% higher compared to the normal activity in said areas, by administering to the mammal in need thereof an efficient amount of the drug delivery system defined in claim 1.

### Claim 16 (depends on 1)

A method of treating a mammal, preferably a human, by administering to the mammal in need thereof an efficient amount of the drug delivery system defined in claim 1.

### Claim 17 (depends on 16)

The method according to claim 16 for the treatment of diseases or conditions associated with a localised increase in extracellular phospholipase A2 activity in mammalian tissue.

### Claim 18 (depends on 17)

The method according to claim 17, wherein the diseases or conditions are selected from the group consisting of inflammatory conditions and cancer.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the type of cancer is selected from the group consisting of brain cancer, breast cancer, lung cancer, colon cancer, ovarian cancer, leukemia, lymphoma, sarcoma and carcinoma.

### Claim 20 (depends on 15)

The method according to claim 15, wherein the increase in extracellular phospholipase A2 activity is a least 25% compared to the normal level of activity in the tissue in question.

### Claim 21 (depends on 20)

A method according to claim 20, wherein the drug delivery system becomes located in diseased tissue after administration and, after degradation by extracellular phospholipase A2, leads to an increase in membrane permeability of cells in the diseased tissue.

### Claim 22 (depends on 20)

A method according to claim 20, wherein the drug delivery system includes a second drug substance, a membrane component, and/or an auxiliary drug substance which acts as an proactivator for extracellular phospholipase A2.

### Claim 23 (depends on 20)

A method according to claim 20, wherein the drug delivery system becomes located in a diseased tissue after administration, and wherein degradation of the drug delivery system by extracellular phospholipase A2 in the diseased tissue is accelerated by a localised increase in temperature in said tissue.

### Claim 24 (depends on 15)

The method according to claim 15 for the treatment of diseases or conditions selected from the group consisting of inflammatory conditions and cancer.

### Claim 25

A lipid based drug delivery system for administration of an second drug substance, wherein the second drug substance is incorporated in the system, said system including lipid derivatives which has (a) an aliphatic group of a length of at least 7 carbon atoms and an organic radical having at least 7 carbon atoms, and (b) a hydrophilic moiety, where the lipid derivative furthermore is a substrate for extracellular phospholipase A2 to the extent that the organic radical can be hydrolytically cleaved off, whereas the aliphatic group remains substantially unaffected, so as to result in an organic acid fragment or an organic alcohol fragment and a lysolipid fragment, said lysolipid fragment not being a substrate for lysophospholipase, said system having included therein lipopolymers or glycolipids so as to present hydrophilic chains on the surface of the system.

### Claim 26 (depends on 25)

A drug delivery system according to claim 25, wherein the lipopolymers or glycolipids are represented by at least a fraction of the prodrug.

### Claim 27 (depends on 25)

A drug delivery system according to claim 25, wherein the polymer of the lipopolymer is selected from polyethylene glycol, poly(lactic acid), poly(glycolic acid), poly(lactic acid)-poly(glycolic acid) copolymers, polyvinyl alcohol, polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatised celluloses.

### Claim 28 (depends on 25)

A drug delivery system according to claim 25, wherein the organic radical which can be hydrolytically cleaved off, is an auxiliary drug substance or an efficiency modifier for the second drug substance.

### Claim 29 (depends on 25)

A drug delivery system according to claim 25, wherein the lipid derivative is a lipid derivative of the following formula:
7
wherein
X and Z independently are selected from O, CH2, NH, NMe, S, S(O), and S(O)2;
Y is —OC(O)—, Y then being connected to R2 via either the oxygen or carbonyl carbon atom;
R1 is an aliphatic group of the formula Y1Y2;
R2 is an organic radical having at least 7 carbon atoms;
where Y1 is —(CH2)n1—(CH═CH)n2—(CH2)n3—(CH═CH)n4—(CH2)n5—(CH═CH)n6—(CH2)n7—(CH═CH)n8r—(CH2)n9, and the sum of n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 9 to 29; n1 is zero or an integer of from 1 to 29, n3 is zero or an integer of from 1 to 20, n5 is zero or an integer of from 1 to 17, n7 is zero or an integer of from 1 to 14, and n9 is zero or an integer of from 1 to 11; and each of n2, n4, n6 and n8 is independently zero or 1; and Y2 is CH3 or CO2H; where each Y1—Y2 independently may be substituted with halogen or C1-4-alkyl,
R3 is selected from phosphatidic acid (PO2—OH), derivatives of phosphatidic acid and bioisosters to phosphatic acid and derivatives thereof.

### Claim 30 (depends on 29)

A drug delivery system according to claim 29, wherein R2 is an aliphatic group of a length of at least 7 carbon atoms.

### Claim 31 (depends on 30)

A drug delivery system according to claim 30, wherein R2 is a group of the formula Y1Y2.

### Claim 32 (depends on 25, 29)

A drug delivery system according to claim 25, wherein at least a fraction of the prodrug is of the formula defined in claim 29, wherein R3 is a derivative of phosphatidic acid to which a polymer selected from polyethylene glycol, poly(lactic acid), poly(glycolic acid), poly(lactic acid)-poly(glycolic acid) copolymers, polyvinyl alcohol, polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatised celluloses, is covalently attached.

### Claim 33 (depends on 25)

A drug delivery system according to claim 25, wherein the lipid derivative constitutes 15-100 mol % of the total dehydrated system.

### Claim 34 (depends on 25)

A drug delivery system according to claim 25, wherein the lipopolymer constitutes 1-50 mol % of the total dehydrated system.

### Claim 35 (depends on 25)

A drug delivery system according to claim 25, wherein the system is in the form of liposomes.

### Claim 36 (depends on 25)

A drug delivery system according to claim 25, wherein the second drug substance is a therapeutically and/or prophylactically active substance selected from (i) antitumor agents, (ii) antibiotics and antifungals, and (iii) antiinflammatory agents.

### Claim 37 (depends on 25)

A pharmaceutical composition comprising the drug delivery system according to claim 25 and optionally a pharmaceutically acceptable carrier.

### Claim 38 (depends on 25)

A method for selectively drug targeting to neoplastic cells, e.g., to areas within the mammalian body, preferably a human, having a extracellular phospholipase A2 activity which is at least 25% higher compared to the normal activity in said areas, by administering to the mammal in need thereof an efficient amount of the drug delivery system defined in claim 25.

### Claim 39 (depends on 25)

A method of treating a mammal, preferably a human, by administering to the mammal in need thereof an efficient amount of the drug delivery system defined in claim 25.

### Claim 40 (depends on 39)

The method according to claim 39 for the treatment of diseases or conditions associated with a localised increase in extracellular phospholipase A2 activity in mammalian tissue.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the diseases or conditions are selected from the group consisting of inflammatory conditions and cancer.

### Claim 42 (depends on 41)

The method according to claim 41, wherein the type of cancer is selected from the group consisting of brain cancer, breast cancer, lung cancer, colon cancer, ovarian cancer, leukemia, lymphoma, sarcoma and carcinoma.

### Claim 43 (depends on 38)

The method according to claim 38, wherein the increase in extracellular phospholipase A2 activity is a least 25% compared to the normal level of activity in the tissue in question.

### Claim 44 (depends on 43)

A method according to claim 43, wherein the drug delivery system becomes located in diseased tissue after administration and, after degradation by extracellular phospholipase A2, leads to an increase in membrane permeability of cells in the diseased tissue.

### Claim 45 (depends on 43)

A method according to claim 43, wherein the drug delivery system includes a second drug substance, a membrane component, and/or an auxiliary drug substance which acts as an proactivator for extracellular phospholipase A2.

### Claim 46 (depends on 43)

A method according to claim 43, wherein the drug delivery system becomes located in a diseased tissue after administration, and wherein degradation of the drug delivery system by extracellular phospholipase A2 in the diseased tissue is accelerated by a localised increase in temperature in said tissue.

### Claim 47 (depends on 38)

The method according to claim 38, wherein the diseases or conditions are selected from the group consisting of inflammatory conditions and cancer.

### Claim 48

A lipid derivative of the following formula:
8
wherein
X and Z independently are selected from O, CH2, NH, NMe, S, S(O), and S(O)2;
Y is —OC(O)—, Y then being connected to R2 via either the oxygen or carbonyl carbon atom;
R1 is an aliphatic group of the formula Y1Y2;
R2 is an organic radical having at least 7 carbon atoms;
where Y1 is —(CH2)n1—(CH═CH)n2—(CH2)n3—(CH═CH)n4—(CH2)n5—(CH═CH)n6—(CH2)n7—(CH═CH)n8r—(CH2)n9, and the sum of n1+2n2+n3+2n4+n5+2n6+n7+2n8+n9 is an integer of from 9 to 29; n1 is zero or an integer of from 1 to 29, n3 is zero or an integer of from 1 to 20, n5 is zero or an integer of from 1 to 17, n7 is zero or an integer of from 1 to 14, and n9 is zero or an integer of from 1 to 11; and each of n2, n4, n6 and n8 is independently zero or 1; and Y2 is CH3 or CO2H; where each Y1—Y2 independently may be substituted with halogen or C1-4-alkyl,
R3 is selected from derivatives of phosphatidic acid to which a hydrophilic polymer is attached.

### Claim 49 (depends on 48)

A lipid derivative according to claim 48, wherein the hydrophilic polymer is selected from polyethylene glycol, poly(lactic acid), poly(glycolic acid), poly(lactic acid)-poly(glycolic acid) copolymers, polyvinyl alcohol, polyvinylpyrrolidone, polymethoxazoline, polyethyloxazoline, polyhydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, and derivatised celluloses.

### Claim 50 (depends on 48)

A lipid derivative according to claim 48, wherein X and Z are O.

### Claim 51 (depends on 48)

A lipid derivative according to claim 48 wherein X and Z are O, R1 and R2 are independently selected from alkyl groups, (CH2)nCH3, where n is 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29; Y is —OC(O)—, Y then being connected to R2 via the carbonyl carbon atom.

### Claim 52 (depends on 48)

A pharmaceutical composition comprising the lipid derivative according to claim 48 and optionally a pharmaceutically acceptable carrier.

### Claim 53 (depends on 52)

A pharmaceutical composition according to claim 52, wherein the lipid derivative is dispersed in the form of a liposome or a micelle.

### Claim 54 (depends on 48)

A method of treating a mammal, preferably a human, by administering to the mammal in need thereof an efficient amount of the lipid derivative defined in claim 48.

### Claim 55 (depends on 54)

The use according to claim 54, wherein the diseases or conditions are selected from the group consisting of inflammatory conditions, and cancer.

### Claim 56 (depends on 55)

The use according to claim 55, wherein the type of cancer is selected from the group consisting of brain cancer, breast cancer, lung cancer, colon cancer, ovarian cancer, leukemia, lymphoma, sarcoma and carcinoma.
